Fig. 2From: A network meta-analysis evaluating the efficacy and safety of adjuvant therapy after nephrectomy in renal cell carcinomaRisk of bias for all randomized controlled trials included in this study. (A) Bar chart of bias; (B) Risk of bias summary. DFS, Disease-free survival; OS, Overall survival; RFS, Recurrence-free survival; AEs, adverse events; IL2 + IFN + 5FU, interleukin-2 + interferon-alpha2a + 5-fluorouracilBack to article page